What is Aniracetam?
Aniracetam (1-[(4-methoxybenzoyl)]-2-pyrrolidoinone) is a nootropic that is derived from piracetam, and the chemical structures of the two compounds are highly similar. Both belong to the racetam chemical class, which are nootropic drugs believed to improve cognition. Unlike piracetam, which is water-soluble, aniractem is fat-soluble and therefore more likely to cross the blood-brain-barrier and exert effects on brain activity. This property means that an equivalent dose of aniracetam is more potent than piracetam (because it is more able to access the brain).
Aniracetam was introduced in 1993 and has been marketed under various trademarked names, including Ampamet, Dragnon, Memodrin, Reset, Sarpul, and Synaptine Elite. It is currently sold in the U.S. as a dietary supplement but is only available by prescription in Europe.
How does it work?
This compound belongs to a group of drugs that are termed “ampakines”, meaning that they affect the function of AMPA (2-amino-3-(5-methyl-3-oxo-1,2- oxazol-4-yl)propanoic acid) receptors. These receptors are present in high concentrations in the hippocampus, which is the region of the brain that is critical for learning and memory and is affected in Alzheimer’s Disease.
The effects of aniracetam on AMPA receptors enhance glutamate neurotransmission, allowing larger numbers of ions to flow into neurons and facilitate their activity. The outcome is improved communication between neurons. Other neurotransmitter systems are also affected: acetylcholine receptors are increased in number and dopamine and serotonin transmission are also improved. Collectively, these effects can improve cognition and optimize brain function.
What Are The Aniracetam Benefits
Here is a quick breakdown of what you can expect to gain from supplementing with aniracetam.
- Enhanced attention and alertness
- enhanced focus
- improved learning and memory
- Increased creativity
The primary benefit of aniracetam in otherwise healthy individuals is enhanced cognition. In general, ampakines improve alertness and attention span, as well as learning and memory. Other users report better perception and increased creativity. It has also been reported to decrease anxiety (anxiolytic properties); in mice, aniracetam increases social interaction via its impact on dopamine and acetylcholine receptors in the brain. In addition, aniracetam has also been shown to have antidepressant-like properties and may be useful in treating mood disorders. One study showed that the compound increased cerebral blood flow, which may also improve cognition.
Aniracetam has also been shown to have positive effects in animal models of traumatic brain injury (TBI), as well as Alzheimer’s patients, who had improved scores on memory tests after 1 and 3 months of use. A study of 60 nursing home residents demonstrated a significant “revitalizing” effect.
Aniracetam Side Effects
Aniracetam has an excellent safety profile in mouse studies. However, unlike its predecessor piracetam, aniracetam has none been extensively tested in human subjects. The above-mentioned studies in Alzheimer’s patients showed that it was non-toxic, although some people have reported mild anxiety. Other side effects include insomnia (if taken late in the day), mild nausea, and headaches.
The recommended dose is 750-1500 mg per day. One study reported that maximum effects on cognition occurred with 1000 mg per day. Because it has a relatively short half-life (approximately 2 hours), this is amount is often divided into two doses, with one taken in the morning and one in the afternoon. Some have reported mild insomnia after taking aniracetam in the evening. Aniracetam is no longer detectable in the blood after 6 hours, so insomnia should not be a problem if the second dose is taken more than 6 hours before bedtime.
Aniracetam is fat-soluble, so it should be taken with foods containing fat. Since aniracetam improves cholinergic neurotransmission, it may also be prudent to take the compound along with foods rich in choline (e.g., meat, seafood, dairy products, soy lecithin). Doing so may also reduce nausea that has been reported as a side effect. Alternatively, some individuals use an artificial acetylcholine precursor, such as 1-alpha glycerylphosphorylcholine (Alpha GPC) in conjunction with aniractem, to maximize its effects on acetylcholine systems in the brain.
Where is the Best Place to Buy Aniracetam?
Your best bet when buying nootropics is that you buy from a vendor that has high quality standards (GMP Certified). It’s also best practice to buy from a company that gets their nootropics third party verified (COA – Certificate of Analysis)
We found through our research that many nootropic aficionado buy their aniracetam from PeakNootropics.com. They are GMP certified and provide a COA. Users say they are transparent and only produce the highest quality nootropics.
Baranova, Anna I., Mark D. Whiting, and Robert J. Hamm. “Delayed, Post-Injury Treatment with Aniracetam Improves Cognitive Performance after Traumatic Brain Injury in Rats.” Journal of Neurotrauma 23.8 (2006): 1233-240. Print.
Dean, Ward, and John Morgenthaler. Smart Drugs & Nutrients: How to Improve Your Memory and Increase Your Intelligence Using the Latest Discoveries in Neuroscience. Santa Cruz, CA: B&J Publications, 1990. Print.
Foltyn, P., P.W. Lucker, J. Schnitker, and N. Wetzelsberger. “A Test Model for Cerebrally-Active Drugs as Demonstrated by the Example of the New Substance Aniracetam.” Arzneimittelforschung. 33.6 (1983): 865-7.
Gualtieri, Fulvio, Dina Manetti, Maria Novella Romanelli, and Carla Ghelardini. “Design and Study of Piracetam-like Nootropics, Controversial Members of the Problematic Class of Cognition-Enhancing Drugs.” Current Pharmaceutical Design 8.2 (2002): 125-38. Print.
Lee, C. R., and P. Benfield. “Aniracetam: an Overview of Its Pharmacodynamic and Pharmacokinetic Properties, and a Review of Its Therapeutic Potential in Senile Cognitive Disorders.” Drugs Aging 4 (1994): 257-73. Print.
Sanacora, Gerard, Carlos A. Zarate, John H. Krystal, and Husseini K. Manji. “Targeting the Glutamatergic System to Develop Novel, Improved Therapeutics for Mood Disorders.” Nature Reviews Drug Discovery 7.5 (2008): 426-37. Print.
Shorvon, Simon. “Pyrrolidone Derivatives.” The Lancet 358.9296 (2001): 1885-892. Print.
Sourander, Leif B., Raija Portin, Pekka Molsa, Anne Lahdes, and Urpo K. Rinne. “Senile Dementia of the Alzheimer Type Treated with Aniracetam: a New Nootropic Agent.” Psychopharmacology 91.1 (1987): 90-95. Print.